A Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) vs placebo in the Treatment of Women With Osteoporosis

Registry ID

EUCTR2005-001511-22

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,

Start date

2005-08-24

Completion date

2016-01-20

Last update

2026-08-16

Conditions

• Postmenopausal Osteoporosis

Summary

Primary Objective for the 12 Month Base Study: To assess the effect of L-001037536 3 mg weekly, 10 mg weekly, 25 mg weekly, and 50 mg weekly on lumbar spine BMD compared to placebo over 12 months. Primary Objective for the Extension Study to 24 Months: To assess the effect of L 001037536 3 mg weekly, 10 mg weekly, 25 mg weekly, and 50 mg weekly on lumbar spine BMD compared to placebo over 24 months.

Locations

• , , Sweden
• , , UK
• , , Denmark

Related clinical trials

• Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females
• Can Serum Lumican Level Identify a Hidden Fragility Phenotype Beyond Bone Mineral Density in Postmenopausal Women?
• StrAtegies For Zoledronic Acid Post-dEnosumab Discontinuation in Postmenopausal oSTeoporosis
• A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study to Evaluate the Safety, Tolerability and Efficacy of AGA2118 in Postmenopausal Women with Low Bone Mineral Density

View on source registry